AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas

Medicine and Dentistry

• Therapeutic Procedure 100%
• Histone Deacetylase Inhibitor 100%
• Meningioma 100%
• Vestibular Schwannoma 100%
• Cells 80%
• Neurinoma 60%
• Growth 40%
• Neoplasm 30%
• Neurofibromatosis Type II 30%
• IC50 30%
• Xenograft 20%
• Man 20%
• Programmed Cell Death 20%
• Combination Therapy 10%
• Diseases 10%
• Chemotherapeutic Agent 10%
• Analysis 10%
• Mechanism of Action 10%
• Assay 10%
• Magnetic Resonance Imaging 10%
• Flow Cytometry 10%
• Phosphotransferase 10%
• Cell Cycle Arrest 10%
• Cell Cycle 10%
• Drug Action 10%
• Meningioma Cell Line 10%
• Autosomal Dominant Inheritance 10%
• Drug Effect 10%
• Intracellular Signaling 10%
• Antiinfective Agent 10%
• Primary Culture 10%
• Cell Cycle Checkpoint 10%
• Immunohistochemistry 10%
• Western Blotting 10%